Reduction of liver metastases outgrowth by tumour antigen-pulsed dendritic cell vaccination by Mels, Anna K et al.
BioMed  Central
Page 1 of 2
(page number not for citation purposes)
Comparative Hepatology
Open Access Proceedings
Reduction of liver metastases outgrowth by tumour antigen-pulsed 
dendritic cell vaccination
Anna K Mels*1, Ilvy Mayen2, Marjolein van Egmond1, Robert HJ Beelen2, 
Sybren Meijer1 and Cornelia D Richters2
Address: 1Surgical Oncology, VU University Medical Centre, Amsterdam, The Netherlands and 2Molecular Cell Biology, VU University Medical 
Centre, Amsterdam, The Netherlands
Email: Anna K Mels* - amels@excerptamedica.com; Ilvy Mayen - amels@excerptamedica.com; Marjolein 
van Egmond - m.vanegmond.cell@med.vu.nl; Robert HJ Beelen - rhj.beelen.cell@med.vu.nl; Sybren Meijer - s.meijer@vumc.nl; 
Cornelia D Richters - cd.richters.cell@med.vu.nl
* Corresponding author    
Introduction
Over 50% of patients diagnosed for primary colorectal
carcinoma develop liver metastases. Partial liver resection
is the single effective treatment improving dismal survival
[1]. Since few patients, however, are candidates for resec-
tion, development of therapies that prevent formation of
liver metastases is warranted.
Outgrowth of metastases may be reduced or prevented by
the action of tumour specific T cells, which are activated
in T cell areas of lymph nodes by professional antigen pre-
senting cells (APC). Dendritic cells (DC) are the most
potent APC, capable of providing the necessary co-stimu-
latory signals [2]. DC have been derived in vitro from
blood monocytes (moDC) for use in clinical trials to gen-
erate tumour specific immune responses, and results of
vaccination studies in melanoma patients are encouraging
[3,4]. However, vaccination for various other cancer types
and treatment of established metastases with antigen-
pulsed DC has been disappointing.
In the present study we investigated whether vaccination
of rats with tumour antigen-pulsed moDC could prevent
outgrowth of experimental liver metastases originating
from colorectal cancer. Additionally, the therapeutic effect
of moDC on existing micrometastases was evaluated.
Methods
Animals
Male Wag/Rij rats (Charles-River, Maastricht, The Nether-
lands) weighing 180–220 g were used in all experiments.
CC531 Tumour Cells
CC531 is an adenocarcinoma cell line, originating in the
colon of Wag/Rij rats exposed to methylazoxymethanol
[5]. CC531 cells were cultured in alpha-RPMI (RPMI 1640
medium, supplemented with 2 mM L-glutamine, 10%
heat-inactivated foetal calf serum (FCS; Gibco, Bio-Cult,
Irvine, Scotland), 50 micromolars beta-mercapto-ethanol,
100 U/ml penicillin and 100 micrograms/ml streptomy-
cin). Cells were detached with trypsin-EDTA solution at
37°C. Viability of cells was assessed by trypan blue exclu-
sion and was always > 95%.
Generation of MoDC
Peripheral blood mononuclear cells were isolated from
heparinized blood by Lymphoprep™ (Axis-Shield PoC AS,
Oslo, Norway) density gradient centrifugation (d = 1.007
g/ml, 20 min at 800 × g) and placed into culture plates for
2 hours. Subsequently, non-adherent cells were removed
and adherent cells were cultured in α-RPMI, containing 5
ng/ml recombinant rat (rr)GM-CSF and rr interleukin
(IL)-4 (PharMingen, San Diego, CA, USA) for 7 days. At
day 7, non-adherent moDC (moDC-) were isolated by
collecting the medium. Viability of cells was always >
95%.
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To generate tumour antigen-pulsed moDC (moDC+), a
mixture of necrotic and apoptotic CC531 tumour cells
was added to moDC- (1:1) at the last day of the 7-day cul-
ture. To generate this antigen mixture, CC531 tumour
cells were treated with UV-B light, cultured for 24 hours
and subsequently subjected to 3 cycles of freezing and
thawing.
Induction of Liver Metastases
Rats underwent small laparotomy under general anaes-
thesia and a loop of the small intestine was exposed.
Under microscopic vision, 1 × 106 live CC531 tumour
cells in 0.5 ml of PBS were inoculated into the mesenteric
vein, followed by ligation of the vein, as described earlier
[6].
Vaccination and Treatment Protocol
Rats were immunised subcutaneously with PBS, tumour
antigens from 35 × 104 necrotic CC531 cells, 35 × 104
moDC- or 35 × 104 moDC+. In the vaccination protocol,
rats were immunised 14 days before inoculation of
CC531 cells. Forty days later, rats were sacrificed. In the
treatment protocol, rats were inoculated with CC531
tumour cells and immunised 3 days later, when microme-
tastases had already developed [7]. Rats were sacrificed
after an additional 21 days.
Number of tumour nodules was counted macroscopi-
cally. Differences were tested using the nonparametric
ANOVA with Kruskal-Wallis post-test. Significance was
accepted at P < 0.05. Results are expressed as mean ± SEM.
Results and Discussion
After vaccination, rats developed 9.1 ± 2.7 (PBS, n = 12),
15.6 ± 5.5 (CC531 tumour antigens, n = 7), 2.7 ± 2.1
(moDC-, n = 7) and 0.8 ± 0.4 (moDC+, n = 12) tumour
nodules. Vaccination with moDC+ reduced outgrowth
compared to PBS (P < 0.01) and CC531 (P < 0.05), indi-
cating that moDC+ vaccination induced effective anti-
tumour immune responses. Previously, rat moDC were
shown to be capable of migrating to draining lymph
nodes and priming T cells in vivo, supporting that injected
moDC are fully functional in vivo [8].
Surprisingly, vaccination with moDC- also induced a
reduction in tumour outgrowth compared to PBS (P <
0.05). This could have been caused by in vivo generation
of bystander T cells directed against foreign FCS compo-
nents, because CC531 cells, moDC- and moDC+ were all
cultured in medium containing FCS. Subsequent recogni-
tion of FCS components on CC531 cells might have initi-
ated tumour cytotoxicity. To exclude bystander effects in
future vaccination experiments, CC531 cells should be
cultured in syngeneic Wag/Rij serum.
None of the four treatment protocols reduced outgrowth
of micrometastases (PBS: 1.4 ± 0.2, n = 5; CC531 antigens:
2.8 ± 1.2, n = 6; moDC-: 1.8 ± 0.4, n = 6; moDC+: 5.2 ±
2.1, n = 5). This could be due to the fact that in vivo gener-
ation of specific T cells after DC vaccination takes several
weeks, during which time tumour cells have the opportu-
nity to spread. Additionally, tumour cells have the capac-
ity to suppress immune responses by production of IL-6
[9] and vascular endothelial growth factor (VEGF) [10]. In
accordance with our earlier data, it might be valuable to
administer adjuvants such as GM-CSF to enhance DC
functionality [6].
Our results indicate that tumour antigen-pulsed DC vacci-
nation may be valuable in the prevention of liver metas-
tases formation in primary colorectal carcinoma.
However, when micrometastases are already present, DC
immunisation seems less effective. Characterisation of
effector cells and optimisation of immunisation is there-
fore essential in future studies.
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